This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keller, R. L.
Right arrow Articles by Clyman, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keller, R. L.
Right arrow Articles by Clyman, R. I.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 112 No. 3 September 2003, pp. 583-587

Persistent Doppler Flow Predicts Lack of Response to Multiple Courses of Indomethacin in Premature Infants With Recurrent Patent Ductus Arteriosus

Roberta L. Keller, MD* and Ronald I. Clyman, MD*,{ddagger}

* Department of Pediatrics
{ddagger} Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California

Objective. Although indomethacin produces ductus arteriosus constriction in extremely premature newborns, a recurrent symptomatic patent ductus arteriosus (PDA) frequently develops after the initial course of indomethacin. Currently, there is little information available to determine the effectiveness of a second course of indomethacin in producing permanent ductus closure. The objective of this study was to determine the rate of permanent ductus closure after a second course of indomethacin for a recurrent, symptomatic PDA and to identify the factors associated with permanent ductus closure.

Methods. We identified 32 infants (<28 weeks’ gestational age) 1) whose ductus was considered to be clinically closed after an initial course of indomethacin and 2) who subsequently developed a symptomatic PDA and received a second course of indomethacin. Clinical variables were evaluated for their association with failure of the second course (defined as surgical ligation after the second course for recurrence of a hemodynamically significant PDA). Data were analyzed by {chi}2 analysis, Fisher’s exact test, and the Mann-Whitney rank sum test.

Results. After the second course of indomethacin, 56% (18 of 32) of the infants had persistent or recurrent PDA-related symptoms that were considered to be hemodynamically significant. The only significant predictor of failure of the second indomethacin course was the demonstration (by Doppler echocardiogram) of persistent ductus flow within 24 hours of completing the initial indomethacin course. All of the 9 newborns with persistent Doppler ductus flow after the initial indomethacin course failed the second course of indomethacin. In contrast, only 39% (9 of 23) of newborns with absent Doppler flow after the initial indomethacin course failed the second course of indomethacin.

Conclusions. Newborns who are <28 weeks’ gestational age and develop a recurrent, symptomatic PDA after completion of an initial indomethacin course rarely respond to multiple courses of indomethacin if there was persistent Doppler evidence of ductus flow after completion of the initial course. Additional indomethacin treatment is unlikely to produce permanent ductus closure.

Key Words: nonsteroidal anti-inflammatory drug

Abbreviations: PDA, patent ductus arteriosus • UCSF, University of California, San Francisco • GA, gestational age

Received for publication Oct 1, 2002; Accepted Mar 20, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
J. Richards, A. Johnson, G. Fox, and M. Campbell
A Second Course of Ibuprofen Is Effective in the Closure of a Clinically Significant PDA in ELBW Infants
Pediatrics, August 1, 2009; 124(2): e287 - e293.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. C. Madan, D. Kendrick, J. I. Hagadorn, I. D. Frantz III, and the National Institute of Child Health and Human D
Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome
Pediatrics, February 1, 2009; 123(2): 674 - 681.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
N. Chorne, C. Leonard, R. Piecuch, and R. I. Clyman
Patent Ductus Arteriosus and Its Treatment as Risk Factors for Neonatal and Neurodevelopmental Morbidity
Pediatrics, June 1, 2007; 119(6): 1165 - 1174.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. Koch, G. Hensley, L. Roy, S. Brown, C. Ramaciotti, and C. R. Rosenfeld
Prevalence of Spontaneous Closure of the Ductus Arteriosus in Neonates at a Birth Weight of 1000 Grams or Less
Pediatrics, April 1, 2006; 117(4): 1113 - 1121.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Jaillard, B. Larrue, T. Rakza, E. Magnenant, H. Warembourg, and L. Storme
Consequences of Delayed Surgical Closure of Patent Ductus Arteriosus in Very Premature Infants
Ann. Thorac. Surg., January 1, 2006; 81(1): 231 - 234.
[Abstract] [Full Text] [PDF]